Cerus (CERS) Cash from Financing Activities (2010 - 2026)
Cerus (CERS) reported Cash from Financing Activities of $1.2 million for Q1 2026, up 11.3% on a YoY basis from $1.1 million in Q1 2025, and up 215.62% sequentially from -$1.0 million in Q4 2025.
Cerus (CERS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Cerus (CERS) has 17 years of Cash from Financing Activities data on file, last reported at $1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 11.3% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $352000.0 (down 25.74% YoY), and the FY2025 full-year result was $231000.0, down 95.35% from the prior year.
- Cash from Financing Activities advanced to $1.2 million in Q1 2026, from -$1.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $7.6 million in Q3 2023 to a low of -$1.4 million in Q2 2024.
- A 5-year average of $1.3 million and a median of $746000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 601.29% in 2023 and sank 710.98% in 2024, its largest moves.
- Tracing CERS's Cash from Financing Activities over 5 years: stood at $457000.0 in 2022, then surged by 158.86% to $1.2 million in 2023, then plunged by 36.94% to $746000.0 in 2024, then sank by 238.2% to -$1.0 million in 2025, then jumped by 215.62% to $1.2 million in 2026.
- Business Quant data shows CERS's Cash from Financing Activities at $1.2 million in Q1 2026, -$1.0 million in Q4 2025, and $320000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -25.00 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 21.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -26.93 Mn |
| 10 | Cerus | 600.87 Mn | 520.44 Mn | 27.89 Mn | 1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.19 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | -1.03 Mn |
| Dec 31, 2025 | -1.03 Mn |
| Sep 30, 2025 | 320,000.00 |
| Sep 30, 2025 | 320,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Mar 31, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 746,000.00 |
| Dec 31, 2024 | 746,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Jun 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | -1.40 Mn |
| Mar 31, 2024 | 5.56 Mn |
| Mar 31, 2024 | 5.56 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Dec 31, 2023 | 1.18 Mn |